Ripronat (meldonium) hard capsules 250 mg. №40

Description

Ripronat (meldonium) hard capsules 250 mg. №40

Composition

active substance: meldonium;

1 hard capsule contains meldonium 250 mg or 500 mg;

excipients: corn starch, colloidal anhydrous silicon dioxide, calcium stearate;

• 250 mg capsule (body and lid): titanium dioxide (E 171), iron oxide yellow (E 172), gelatin;
• 500 mg capsule (body and cap): titanium dioxide (E 171), iron oxide yellow (E 172), quinoline yellow (E 104), azorubin (E 122), Ponceau 4R (E 124), gelatin.

Medicinal form

Capsules are hard.

The main physical and chemical properties:

• capsules of 250 mg: hard shiny capsules of beige color, containing homogeneous powder of white or almost white color;
• capsules of 500 mg: hard shiny capsules with a red cap and a beige body, containing a homogeneous white or almost white powder.

Pharmacotherapeutic group

Other cardiac drugs.
ATX code C01E B22.

Pharmacological properties

It is a remedy that improves metabolic processes in the heart muscle. In conditions of ischemia (insufficient blood supply), it restores the cellular balance between oxygen consumption and its delivery, prevents disruption of ATP transport, activates glycolysis without additional oxygen consumption. It helps to increase performance, reduce the severity of signs of physical and mental overstrain, activate immunity. Has a cardioprotective effect. In case of acute ischemic myocardial injury, it reduces the zone of necrosis and shortens the rehabilitation period.

Indications

Ripronat capsules is used:

• with diseases of the heart, vascular system (chronic insufficiency, stable exertional angina, cardiomyopathy, functional disorders);
• with acute / chronic disorders of cerebral circulation;
• with reduced performance, psychoemotional or physical overstrain;
• during the recovery period after head injuries, cerebrovascular disorders, encephalitis.

Contraindications

Ripronat capsules is contraindicated:

• with intolerance to the components of the drug;
• with increased intraocular pressure;
• with severe dysfunction of the liver, kidneys.

Application during pregnancy and lactation

Contraindicated.

Method of administration and dosage

Ripronat capsules is administered orally, preferably in the morning.
The standard dose for adults with diseases of the heart, vascular system – 500-1000 mg / day, maximum – 1000 mg / day.
Standard doses for acute / chronic disorders of cerebral circulation – 500 mg / day, maximum – 500 mg / day.
The duration of therapy is 4-6 weeks with a frequency of 2-3 times a year.

Overdose

The drug Ripronat capsules is low toxic.
Possible symptoms: decreased blood pressure, tachycardia, dizziness, weakness.
Treatment is symptomatic. Monitoring of kidney and liver function is required.

Side effects:

• Urinary disorders: pollakiuria.
• Immune disorders: allergic dermatitis, urticaria, angioedema, anaphylactic reactions.
• Mental disorders: sleep disturbances, fear, agitation, obsessive thoughts.
• Neurological disorders: paresthesia, cephalalgia, tremor, vertigo, hypesthesia, tinnitus, gait disturbance, loss of consciousness.
• Cardiovascular disorders: palpitations, cardiac arrhythmias, tachycardia, discomfort in the region of the heart, atrial fibrillation, instability of blood pressure, hyperemia, skin pallor, hypertensive crisis.
• Respiratory disorders: pharyngitis, cough, apnea, dyspnea.
• Gastrointestinal disorders: dyspepsia, loss of appetite, dysgeusia (metallic taste in the mouth), nausea, diarrhea, flatulence, hypersalivation, dry mouth.
• Dermatological disorders: macular, papular eruptions, itching.
• Musculoskeletal disorders: back pain, myasthenia gravis, muscle spasms.
• General: weakness, asthenia, chills, swelling of the legs, face, cold sweat, hot or cold sensation.
• Laboratory changes: increased levels of C-reactive protein, dyslipidemia, abnormalities in the electrocardiogram, eosinophilia, tachycardia.